Pharmaceutical

AltruBio secures $225m for immune checkpoint programme development

AltruBio has secured $225m in an oversubscribed Series B financing round to propel the clinical development of its ICE programme.

May 23, 2024 - 04:00
AltruBio secures $225m for immune checkpoint programme development
AltruBio has secured $225m in an oversubscribed Series B financing round to propel the clinical development of its ICE programme.
Read the original article

Tags:

Previous Article

Alvotech and Dr Reddy’s partner to commercialise AVT03

Next Article

Endeavor’s IPF Drug Linked to Improved Lung Function in Phase 2 Study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA withdraws approval of preterm birth drug Makena

FDA withdraws approval of preterm birth drug Makena

Apr 8, 2023

Digital twins: A new path to personalised medicine

Digital twins: A new path to personalised medicine

Oct 16, 2024

STAT+: Pharmalittle: We’re reading about a FTC probe into GPOs, a frostbite drug, and more

STAT+: Pharmalittle: We’re reading about a FTC probe in...

Feb 15, 2024